| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2142863 | Lung Cancer | 2010 | 7 Pages |
Abstract
Global and specific health-related QoL data similar in both treatment groups with no statistically significant difference. Efficacy measures, overall response rate, time-to-progression and overall survival were equivalent in both arms. However, severe anemia and febrile neutropenia are statistically more frequent in the VNR/CDDP arm than in the DCT/CDDP one. These data should be considered in treatment decision-making for pts with advanced non-small-cell lung cancer and for the design of future trials with chemotherapy plus biologics.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Vittorio Gebbia, Vito Lorusso, Domenico Galetta, Michele Caruso M, Giuseppe Palomba, Fernando Riccardi, Nicolò Borsellino, Francesco Carrozza, Silvana Leo, Francesco Ferraù, Saverio Cinieri, Gianfranco Mancuso, Sergio Mancarella, Giuseppe Colucci,